Literature DB >> 17680773

Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands.

Aphrodite Caragounis1, Tai Du, Gulay Filiz, Katrina M Laughton, Irene Volitakis, Robyn A Sharples, Robert A Cherny, Colin L Masters, Simon C Drew, Andrew F Hill, Qiao-Xin Li, Peter J Crouch, Kevin J Barnham, Anthony R White.   

Abstract

Biometals have an important role in AD (Alzheimer's disease) and metal ligands have been investigated as potential therapeutic agents for treatment of AD. In recent studies the 8HQ (8-hydroxyquinoline) derivative CQ (clioquinol) has shown promising results in animal models and small clinical trials; however, the actual mode of action in vivo is still being investigated. We previously reported that CQ-metal complexes up-regulated MMP (matrix metalloprotease) activity in vitro by activating PI3K (phosphoinositide 3-kinase) and JNK (c-jun N-terminal kinase), and that the increased MMP activity resulted in enhanced degradation of secreted Abeta (amyloid beta) peptide. In the present study, we have further investigated the biochemical mechanisms by which metal ligands affect Abeta metabolism. To achieve this, we measured the effects of diverse metal ligands on cellular metal uptake and secreted Abeta levels in cell culture. We report that different classes of metal ligands including 8HQ and phenanthroline derivatives and the sulfur compound PDTC (pyrrolidine dithiocarbamate) elevated cellular metal levels (copper and zinc), and resulted in substantial loss of secreted Abeta. Generally, the ability to inhibit Abeta levels correlated with a higher lipid solubility of the ligands and their capacity to increase metal uptake. However, we also identified several ligands that potently inhibited Abeta levels while only inducing minimal change to cellular metal levels. Metal ligands that inhibited Abeta levels [e.g. CQ, 8HQ, NC (neocuproine), 1,10-phenanthroline and PDTC] induced metal-dependent activation of PI3K and JNK, resulting in JNK-mediated up-regulation of metalloprotease activity and subsequent loss of secreted Abeta. The findings in the present study show that diverse metal ligands with high lipid solubility can elevate cellular metal levels resulting in metalloprotease-dependent inhibition of Abeta. Given that a structurally diverse array of ligands was assessed, the results are consistent with the effects being due to metal transport rather than the chelating ligand interacting directly with a receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680773      PMCID: PMC2275059          DOI: 10.1042/BJ20070579

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

1.  The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice.

Authors:  Joo-Yong Lee; Jonathan E Friedman; Itzchak Angel; Alex Kozak; Jae-Young Koh
Journal:  Neurobiol Aging       Date:  2004 Nov-Dec       Impact factor: 4.673

2.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.

Authors:  G G Glenner; C W Wong
Journal:  Biochem Biophys Res Commun       Date:  1984-05-16       Impact factor: 3.575

3.  Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart.

Authors:  P Y Cheung; G Sawicki; M Wozniak; W Wang; M W Radomski; R Schulz
Journal:  Circulation       Date:  2000-04-18       Impact factor: 29.690

4.  Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis.

Authors:  Kevin J Barnham; William J McKinstry; Gerd Multhaup; Denise Galatis; Craig J Morton; Cyril C Curtain; Nicholas A Williamson; Anthony R White; Mark G Hinds; Raymond S Norton; Konrad Beyreuther; Colin L Masters; Michael W Parker; Roberto Cappai
Journal:  J Biol Chem       Date:  2003-02-28       Impact factor: 5.157

5.  Modulation of mitochondrial membrane potential and reactive oxygen species production by copper in astrocytes.

Authors:  Armen V Gyulkhandanyan; Chris J Feeney; Peter S Pennefather
Journal:  J Neurochem       Date:  2003-10       Impact factor: 5.372

6.  Effect of 5-chloro-7-iodo-8-hydroxy-quinoline (clioquinol) on the uptake and distribution of nickel, zinc and mercury in mice.

Authors:  H Tjälve; K Ståhl
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1984-07

7.  Mechanisms of Zn(2+)-induced signal initiation through the epidermal growth factor receptor.

Authors:  James M Samet; Brian J Dewar; Weidong Wu; Lee M Graves
Journal:  Toxicol Appl Pharmacol       Date:  2003-08-15       Impact factor: 4.219

8.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

Authors:  Craig W Ritchie; Ashley I Bush; Andrew Mackinnon; Steve Macfarlane; Maree Mastwyk; Lachlan MacGregor; Lyn Kiers; Robert Cherny; Qiao-Xin Li; Amanda Tammer; Darryl Carrington; Christine Mavros; Irene Volitakis; Michel Xilinas; David Ames; Stephen Davis; Konrad Beyreuther; Rudolph E Tanzi; Colin L Masters
Journal:  Arch Neurol       Date:  2003-12

9.  Partial purification of a metalloprotease catalyzing the processing of adrenodoxin precursor in bovine adrenal cortex mitochondria.

Authors:  Y Sagara; A Ito; T Omura
Journal:  J Biochem       Date:  1984-12       Impact factor: 3.387

10.  Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Authors:  C L Masters; G Simms; N A Weinman; G Multhaup; B L McDonald; K Beyreuther
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

View more
  10 in total

1.  Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.

Authors:  Hailin Zheng; Moussa B H Youdim; Mati Fridkin
Journal:  ACS Chem Neurosci       Date:  2010-10-04       Impact factor: 4.418

2.  Higher aluminum concentration in Alzheimer's disease after Box-Cox data transformation.

Authors:  Robert Rusina; Radoslav Matěj; Lucie Kašparová; Jaromír Kukal; Pavel Urban
Journal:  Neurotox Res       Date:  2011-05-13       Impact factor: 3.911

Review 3.  Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.

Authors:  Ralf G Rempe; Anika M S Hartz; Björn Bauer
Journal:  J Cereb Blood Flow Metab       Date:  2016-06-20       Impact factor: 6.200

Review 4.  Alzheimer's disease & metals: therapeutic opportunities.

Authors:  Vijaya B Kenche; Kevin J Barnham
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

5.  Copper and zinc bis(thiosemicarbazonato) complexes with a fluorescent tag: synthesis, radiolabelling with copper-64, cell uptake and fluorescence studies.

Authors:  SinChun Lim; Katherine A Price; Siow-Feng Chong; Brett M Paterson; Aphrodite Caragounis; Kevin J Barnham; Peter J Crouch; Josephine M Peach; Jonathan R Dilworth; Anthony R White; Paul S Donnelly
Journal:  J Biol Inorg Chem       Date:  2009-09-22       Impact factor: 3.358

6.  Zinc Inhibits Amyloid beta Production from Alzheimer's Amyloid Precursor Protein in SH-SY5Y Cells.

Authors:  Jinu Lee; Chul Hoon Kim; Dong Goo Kim; Young Soo Ahn
Journal:  Korean J Physiol Pharmacol       Date:  2009-06-30       Impact factor: 2.016

Review 7.  The role of metals in modulating metalloprotease activity in the AD brain.

Authors:  Gulay Filiz; Katherine A Price; Aphrodite Caragounis; Tai Du; Peter J Crouch; Anthony R White
Journal:  Eur Biophys J       Date:  2008-02-13       Impact factor: 1.733

8.  Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation.

Authors:  Peter J Crouch; Lin Wai Hung; Paul A Adlard; Mikhalina Cortes; Varsha Lal; Gulay Filiz; Keyla A Perez; Milawaty Nurjono; Aphrodite Caragounis; Tai Du; Katrina Laughton; Irene Volitakis; Ashley I Bush; Qiao-Xin Li; Colin L Masters; Roberto Cappai; Robert A Cherny; Paul S Donnelly; Anthony R White; Kevin J Barnham
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

9.  Neurodegeneration in Alzheimer disease: role of amyloid precursor protein and presenilin 1 intracellular signaling.

Authors:  Mario Nizzari; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Aldo Pagano; Carola Porcile; Claudio Russo; Tullio Florio
Journal:  J Toxicol       Date:  2012-02-08

10.  Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy.

Authors:  Kavita Gaur; Alexandra M Vázquez-Salgado; Geraldo Duran-Camacho; Irivette Dominguez-Martinez; Josué A Benjamín-Rivera; Lauren Fernández-Vega; Lesly Carmona Sarabia; Angelys Cruz García; Felipe Pérez-Deliz; José A Méndez Román; Melissa Vega-Cartagena; Sergio A Loza-Rosas; Xaymara Rodriguez Acevedo; Arthur D Tinoco
Journal:  Inorganics (Basel)       Date:  2018-11-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.